Report: Sales of drugs approved this year could hit $18.7B in 5 years

11/14/2013 | American City Business Journals

A report from EP Vantage forecasts that the combined sales of 34 drugs expected to be approved in the U.S. this year could reach a record $18.7 billion by 2018, up 14% from the estimated five-year revenue of 43 drugs cleared last year. If approved before the year ends, Gilead Sciences' hepatitis C drug sofosbuvir will be the top revenue-generating drug with expected sales of $3 billion by 2018, followed by Biogen Idec's Tecfidera with $2.9 billion in potential sales.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
Nationwide, SL_Nationwide
Finance Manager - ENT
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA